We expect Novavax NVAX to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell.

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

The US Department of Health and Human Services said Thursday that it aims to accomplish within four years a scientific feat ...

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...

The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled ...

The potential change outlined in a statement would require all new vaccines to undergo placebo testing, sparking concerns ...

Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...

The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.

While Vaxart can proceed with its study, fellow COVID-19 vaccine developers GeoVax and Novavax continue to be hamstrung by ...

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...

Novavax said Monday that the FDA was asking the company to run a new clinical trial of its vaccine after the agency grants full approval. The company said it had responded and tha ...